—Data from five abstracts include Phase I and
preclinical animal studies accepted as oral and poster
presentations—
—VERONA Phase II clinical development program
underway in The Netherlands—
The Medicines Company (NASDAQ:MDCO) today announced that
five abstracts with data from its investigational anesthetic
MDCO-700 (formerly, ABP-700) development program will be presented
at ANESTHESIOLOGY® 2016, the annual meeting of the American Society
of Anesthesiologists (ASA), being held at the McCormick Place in
Chicago from October 22-26, 2016 and at the International Society
for Anaesthetic Pharmacology 25th Annual Meeting (ISAP) taking
place at the Hyatt Regency Chicago on October 21, 2016.
Investigators will present data from the MDCO-700 Phase I
clinical program and preclinical animal studies evaluating infusion
optimization, safety, tolerability and pharmacokinetic and
pharmacodynamic parameters at both meetings in the form of oral and
poster presentations.
Details of ASA presentations are provided
below:
Date Time Product Event Place
SATURDAYOctober 22
10:30am-11am MDCO-700 (ABP-700)
Session: Poster Presentations:Anesthetic
Action and Biochemistry
Effect on ECG Parameters of ABP-700
Infusions inCombination With Opiates Targeting Sedation in Man
Lead author: Peter Meyer, University
Medical Center Groningen
Hall F-FoyerArea B(Monitor 07,
presentation #A1034)
SATURDAYOctober 22
10:30am -12pm MDCO-700 (ABP-700)
Session: Anesthetic Action and
Biochemistry
The Novel Soft-Etomidate Analogue
ABP-700Increases Seizure Threshold in Rodents
Lead author: Dario Lehoux, The Medicines
Company
Convention Center Room:W476 (Oral
presentation #A1106)
WEDNESDAYOctober 26
8:00am-9:30am MDCO-700 (ABP-700)
Session: Drug Disposition, Metabolism and
Elimination
A PK-PD Model for the Novel
PositiveAllosteric GABA Receptor Modulator ABP-700
Lead author: Douglas Eleveld,
UniversityMedical Center Groningen
Convention Center Room:W474b (Oral
presentation #A5009)
Details of ISAP presentations are provided
below:
Date
Time
Product
Event
Place
FRIDAYOctober 21
9:00am MDCO-700 (ABP-700)
Session: Poster Presentations
Effect on ECG Parameters of ABP-700
Infusions inCombination With Opiates Targeting Sedation in Man
Lead author: Peter Meyer, University
MedicalCenter Groningen
Hyatt Regency Chicago(Room #TBD)
FRIDAYOctober 21
9:00am MDCO-700 (ABP-700)
Session: Poster Presentation
A Phase 1 Dose Optimization Study of
ABP-700with Opiates and/or Midazolam TargetingInduction of General
Anesthesia (Preliminary Results)
Lead author: Sascha Meyer, University
MedicalCenter Groningen
Hyatt Regency Chicago(Room #TBD)
About MDCO-700
MDCO-700 (formerly, ABP-700), an investigational product not
approved for commercial use in any market, is a novel, positive
allosteric modulator of the GABA-A receptor currently being
developed for the induction of general anesthesia and procedural
sedation. MDCO-700 is from a family of compounds invented by
Dr. Douglas Raines at the Massachusetts General
Hospital.
About The Medicines Company
The Medicines Company is a biopharmaceutical company
driven by an overriding purpose—to save lives, alleviate suffering
and contribute to the economics of healthcare. The Company's
mission is to create transformational solutions to address the most
pressing healthcare needs facing patients, physicians and providers
in three critical therapeutic areas: serious infectious disease
care, cardiovascular care and surgery and perioperative care. The
Company is headquartered in Parsippany, New Jersey, with
global innovation centers
in California and Switzerland.
Forward Looking Statements
Statements contained in this press release that are not purely
historical may be deemed to be forward-looking statements for
purposes of the safe harbor provisions under The Private Securities
Litigation Reform Act of 1995. Without limiting the foregoing, the
words "believes," "anticipates," "expects," “views” and similar
expressions are intended to identify forward-looking statements.
These forward-looking statements involve known and unknown risks
and uncertainties that may cause the Company's actual results,
levels of activity, performance or achievements to be materially
different from those expressed or implied by these forward-looking
statements. Important factors that may cause or contribute to such
differences include whether the clinical trials for our product
candidates, including MDCO-700, will advance in the clinical
process on a timely basis, or at all, or succeed in achieving their
specified endpoints; whether the Company is able to disclose
clinical trial results on a timely basis; whether physicians,
patients and other key decision makers will accept clinical trial
results; whether the Company will make regulatory submissions for
its product candidates on a timely basis, or at all; whether its
regulatory submissions will receive approvals from regulatory
agencies on a timely basis, or at all; and such other factors as
are set forth in the risk factors detailed from time to time in the
Company's periodic reports and registration statements filed with
the Securities and Exchange Commission including, without
limitation, the risk factors detailed in the Company's quarterly
report on Form 10-Q filed with the Securities and Exchange
Commission on August 5, 2016 , which are incorporated herein by
reference. The Company specifically disclaims any obligation to
update these forward-looking statements.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20161013005314/en/
MediaRusso PartnersMatt
Middleman, M.D.,
212-845-4272matt.middleman@russopartnersllc.comorInvestorsThe Medicines CompanyKrishna
Gorti, M.D., 973-290-6122Vice President, Investor
Relationskrishna.gorti@themedco.com
Medicines (NASDAQ:MDCO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Medicines (NASDAQ:MDCO)
Historical Stock Chart
From Apr 2023 to Apr 2024